Hanlon Investment Management Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206 shares of the company’s stock after selling 62 shares during the period. Hanlon Investment Management Inc.’s holdings in Johnson & Johnson were worth $213,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the period. State Street Corp increased its position in Johnson & Johnson by 0.6% during the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after buying an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after buying an additional 805,831 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Johnson & Johnson by 2.3% in the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after acquiring an additional 421,779 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after acquiring an additional 328,297 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.
Analyst Ratings Changes
A number of analysts have issued reports on JNJ shares. StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Morgan Stanley dropped their price objective on Johnson & Johnson from $180.00 to $179.00 in a report on Monday. SVB Leerink reduced their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Finally, Guggenheim assumed coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $173.60.
Johnson & Johnson Trading Down 0.5 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter last year, the business posted $2.13 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- This Is Why Penny Stock GreenPower Motor Company Is A Win
- Comcast Sum of All Parts is Producing a Cumulative Effect
- The Greenbrier Companies: All Aboard For High-Yield In 2023
- Coty Stock is on the Comeback Trail
- Splunk Stock is an AI-Powered Enterprise SEIM Play
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
